The Food and Drug Administration said it granted traditional approval to Eli Lilly’s Retevmo for adult and pediatric patients two years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. Retevmo received accelerated approval for this indication for patients 12 years of age and older in 2020.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FDA AdCom on Eli Lilly’s donanemab better than anticipated, says Cantor
- Eli Lilly Stock (LLY) Gained on FDA Panel Approval
- FDA panel votes 11-0 Eli Lilly Alzheimer’s drug benefits outweigh risks
- FDA panel votes 11-0 Eli Lilly drug efficacious in Alzheimer’s, Bloomberg says
- Eli Lilly announces detailed results from Phase 2 SYNERGY-NASH trial